DE60308332T2 - Chinazolin-Verbindungen mit therapeutischem Nutzen - Google Patents

Chinazolin-Verbindungen mit therapeutischem Nutzen Download PDF

Info

Publication number
DE60308332T2
DE60308332T2 DE60308332T DE60308332T DE60308332T2 DE 60308332 T2 DE60308332 T2 DE 60308332T2 DE 60308332 T DE60308332 T DE 60308332T DE 60308332 T DE60308332 T DE 60308332T DE 60308332 T2 DE60308332 T2 DE 60308332T2
Authority
DE
Germany
Prior art keywords
preparation
mmol
solution
het
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60308332T
Other languages
German (de)
English (en)
Other versions
DE60308332D1 (de
Inventor
Julian Pfizer Global Research and De BLAGG
Michael J. Pfizer Central Research & FRAY
Mark L. Pfizer Central Research and LEWIS
John P. Pfizer Central Research and MATHIAS
Mark H. Pfizer Central Research & De STEFANIAK
Alan Pfizer Global Research and Devl STOBIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60308332D1 publication Critical patent/DE60308332D1/de
Application granted granted Critical
Publication of DE60308332T2 publication Critical patent/DE60308332T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60308332T 2002-03-14 2003-03-05 Chinazolin-Verbindungen mit therapeutischem Nutzen Expired - Fee Related DE60308332T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0206033 2002-03-14
GBGB0206033.3A GB0206033D0 (en) 2002-03-14 2002-03-14 Compounds useful in therapy
PCT/IB2003/000998 WO2003076427A1 (en) 2002-03-14 2003-03-05 Quinazoline compounds useful in therapy

Publications (2)

Publication Number Publication Date
DE60308332D1 DE60308332D1 (de) 2006-10-26
DE60308332T2 true DE60308332T2 (de) 2007-01-11

Family

ID=9932974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60308332T Expired - Fee Related DE60308332T2 (de) 2002-03-14 2003-03-05 Chinazolin-Verbindungen mit therapeutischem Nutzen

Country Status (19)

Country Link
US (1) US6936619B2 (es)
EP (1) EP1483257B1 (es)
JP (1) JP2005532275A (es)
AR (1) AR038949A1 (es)
AT (1) ATE339414T1 (es)
AU (1) AU2003209594A1 (es)
BR (1) BR0308407A (es)
CA (1) CA2479016A1 (es)
DE (1) DE60308332T2 (es)
ES (1) ES2271618T3 (es)
GB (1) GB0206033D0 (es)
GT (1) GT200300059A (es)
HN (1) HN2003000100A (es)
MX (1) MXPA04008939A (es)
PA (1) PA8569501A1 (es)
PE (1) PE20040265A1 (es)
TW (1) TW200305420A (es)
UY (1) UY27711A1 (es)
WO (1) WO2003076427A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ES2270143T3 (es) * 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
US20040132728A1 (en) * 2002-09-17 2004-07-08 Pfizer Inc Combinations of atorvastatin and alpha1adrenergic receptor antagonists
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
AU2004255585A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
ES2427999T3 (es) 2007-04-17 2013-11-05 Evotec Ag Compuestos heterocíclicos 2-cianofenil-condensados y composiciones y usos de los mismos
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
MY146924A (en) 2007-06-21 2012-10-15 Cara Therapeutics Inc Substituted imidazoheterocycles
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2010014666A2 (en) 2008-07-31 2010-02-04 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PE20191204A1 (es) 2012-08-06 2019-09-10 Firmenich Incorporated Modificador del sabor dulce
WO2014060852A2 (en) * 2012-10-15 2014-04-24 Resverlogix Corp. Compounds useful in the synthesis of benzamide compounds
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
TN2016000254A1 (en) * 2013-12-20 2017-10-06 Esteve Labor Dr Fused imidazolyl derivatives, their preparation and use as medicaments.
CA2943889A1 (en) * 2014-05-28 2015-12-03 F. Hoffmann-La Roche Ag 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法
MY196319A (en) 2015-12-17 2023-03-24 Merck Patent Gmbh Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
JP6950534B2 (ja) * 2016-01-29 2021-10-13 小野薬品工業株式会社 テトラヒドロナフタレン誘導体
WO2018031434A1 (en) * 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085213A (en) * 1976-01-28 1978-04-18 Pfizer Inc. Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物

Also Published As

Publication number Publication date
MXPA04008939A (es) 2004-11-26
CA2479016A1 (en) 2003-09-18
DE60308332D1 (de) 2006-10-26
PE20040265A1 (es) 2004-05-01
GT200300059A (es) 2003-10-15
BR0308407A (pt) 2005-01-11
GB0206033D0 (en) 2002-04-24
EP1483257B1 (en) 2006-09-13
EP1483257A1 (en) 2004-12-08
UY27711A1 (es) 2003-10-31
WO2003076427A1 (en) 2003-09-18
US6936619B2 (en) 2005-08-30
ES2271618T3 (es) 2007-04-16
HN2003000100A (es) 2003-12-15
ATE339414T1 (de) 2006-10-15
PA8569501A1 (es) 2003-12-10
AU2003209594A1 (en) 2003-09-22
US20040029859A1 (en) 2004-02-12
TW200305420A (en) 2003-11-01
JP2005532275A (ja) 2005-10-27
AR038949A1 (es) 2005-02-02
WO2003076427A8 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
DE60308332T2 (de) Chinazolin-Verbindungen mit therapeutischem Nutzen
DE60124577T2 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
TWI817189B (zh) 作為fgfr4抑制劑之雙環雜環
DE60130555T2 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
EP2751106B1 (de) Substituierte annellierte pyrimidine und ihre verwendung
DE69921358T2 (de) Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
DE60021630T2 (de) Tricyclische kondensierte heterocyclische Verbindungen als CRF Antagonisten
DE60225563T2 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
CA2515343C (en) Antiparasitic terpene alkaloids
EP1742945B1 (de) Substituierte phenylaminopyrimidine
AU2018237123B2 (en) Bruton's tyrosine kinase inhibitors
JP7064512B2 (ja) キナーゼ阻害剤およびその使用
OA13050A (en) 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
EP1515965B1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
EA017144B1 (ru) N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
KR20150059647A (ko) 키나제 억제제로서 유용한 이미다조트리아진카르보니트릴
AU2008246351A1 (en) Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
SG184534A1 (en) Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
DE602004005960T2 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
KR20190020343A (ko) 벤조디옥산 유도체 및 이의 약제학적 용도
US4804665A (en) Azaspiro compounds and their use
CA3093706A1 (en) Jak inhibitors
DE69332929T2 (de) ANTIALLERGISCHE IMIDAZO[1,2-a]THIENO[2,3-d]AZEPINDERIVATE
EP3296298A1 (de) 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee